| scholarly article | Q13442814 |
| P50 | author | Jerome Robert | Q56858042 |
| P2093 | author name string | Vincent Jarlier | |
| Roland Bismuth | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | methicillin-resistant Staphylococcus aureus | Q595158 |
| Staphylococcus aureus | Q188121 | ||
| P1104 | number of pages | 5 | |
| P304 | page(s) | 506-510 | |
| P577 | publication date | 2006-01-12 | |
| P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
| P1476 | title | Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002 | |
| P478 | volume | 57 |
| Q37443022 | Bench-to-bedside review: Understanding the impact of resistance and virulence factors on methicillin-resistant Staphylococcus aureus infections in the intensive care unit |
| Q37392738 | Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis |
| Q40182765 | D-cycloserine increases the effectiveness of vancomycin against vancomycin-highly resistant Staphylococcus aureus. |
| Q34067779 | Daptomycin as a possible new treatment option for surgical management of Methicillin-Resistant Staphylococcus aureus sternal wound infection after cardiac surgery. |
| Q42270981 | Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus |
| Q37765900 | Emerging drugs for complicated skin and skin-structure infections |
| Q36718474 | Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections |
| Q45149079 | Etest versus vitek 2 vancomycin minimum inhibitory concentration testing methods for methicillin-resistant staphylococcus aureus: an antimicrobial stewardship initiative to evaluate the degree of discordance among methods at a rural tertiary hospita |
| Q37392917 | Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. |
| Q37670532 | Fluoroquinolone Therapy in Staphylococcus aureus Infections: Where Do We Stand? |
| Q98164449 | Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis |
| Q58777717 | Impact of teicoplanin maintenance dose and MIC values on the clinical outcomes of patients treated for methicillin-resistant bacteremia |
| Q33559139 | In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa |
| Q41387835 | Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center |
| Q42931892 | Increased vancomycin minimum inhibitory concentration among Staphylococcus aureus isolates in Malaysia |
| Q46826194 | Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia |
| Q36856946 | Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? |
| Q40600332 | Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. |
| Q35679714 | Isolation and Host Range of Bacteriophage with Lytic Activity against Methicillin-Resistant Staphylococcus aureus and Potential Use as a Fomite Decontaminant |
| Q47253276 | Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07. |
| Q36916064 | Microbiology of antibiotic resistance in Staphylococcus aureus. |
| Q28078930 | Molecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureus |
| Q37247772 | Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections |
| Q42946341 | Quantitative differences in antibiotic resistance between methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains isolated in Hungary, Austria and Macedonia. |
| Q37982066 | Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep'): implications for therapy |
| Q24646677 | Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications |
| Q40333300 | Synergistic effects of vancomycin and β-lactams against vancomycin highly resistant Staphylococcus aureus. |
| Q26796560 | Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates |
| Q44322532 | Treatment of resistant Gram-positive bacterial infections |
| Q37600389 | Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria |
| Q42369114 | Trend of vancomycin susceptibility of staphylococci at a level 1 trauma centre of India |
Search more.